[Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia].
OBJECTIVE
To compare efficacy and tolerance of polycosanol vs besafibrate in patients with hypercholesterolemia (HCE).


METHODS
A multicenter controlled double blind randomised trial entered 113 patients with HCE. After 5 weeks of diet the patients were randomised into two groups. 59 patients of group 1 received polycosanol (10 mg/day), 54 patients of group 2 were given besafibrate (400 mg/day) for 8 weeks.


RESULTS
The 8-week course of treatment was completed by 103 patients (91%): 57(97%) patients of group 1 and 46(85%) patients of group 2. In group 1 total cholesterol diminished by an average of 15%, LDLP cholesterol fell by 18%, triglycerides by 15%, while in group 2 a respective decrease was 8, 11 and 6%. Side effects in group 1 were mild.


CONCLUSIONS
A hypolipidemic effect of polycosanol in a daily dose 10 mg is superior to that of besafibrate in a daily dose 400 mg.
Nikitin
Iu P
IuP
Slepchenko
N V
NV
Gratsianskiĭ
N A
NA
Nechaev
A S
AS
Syrkin
A L
AL
Poltavskaia
M G
MG
Sumarokov
A V
AV
Revazov
A V
AV
D004311:Double-Blind Method; D005233:Fatty Alcohols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012426:Russia
D005233:Fatty Alcohols; D000960:Hypolipidemic Agents; C044309:1-octacosanol
Rezul'taty rossiĭskogo mnogotsentrovogo kontroliruemogo issledovaniia gipolipidemicheskogo preparata polikosanol.